Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DRG1 pseudogene 2 (DRG1P2) is a non-protein-coding genomic segment related to the developmentally regulated GTP binding protein 1 (DRG1)[1][2][3]. Pseudogenes, such as DRG1P2, are typically characterized by sequence similarity to their parental protein-coding genes but contain disabling mutations that prevent them from encoding functional proteins[5]. While some pseudogenes are transcribed and might offer regulatory functions at the RNA level, there is no current evidence that DRG1P2 has such a role. DRG1, the parent gene of DRG1P2, participates in protein translation, microtubule regulation, and cell growth, with disease associations including cancer and neurodegeneration[1][3][6]. However, DRG1P2 itself is not considered a therapeutic target, nor is it involved in these biological processes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Developmentally regulated GTP binding protein 1 pseudogene 2 (DRG1P2).